Table 5.
Tumor Compression | CIPN | Postsurgical | Postradiation | Total | |
---|---|---|---|---|---|
Total number of patients | n = 13 | n = 25 | n = 13 | n = 6 | N = 57 |
Total number of infusions | n = 34 | n = 113 | n = 32 | n = 13 | N = 192 |
Any adverse event during ketamine course (% based on total number of patients) | |||||
Yes | 5 (38.5) | 14 (56.0) | 6 (46.2) | 0 (0.0) | 25 (43.9) |
No | 8 (61.5) | 11 (44.0) | 7 (53.8) | 6 (100.0) | 32 (56.1) |
P value | 0.41 | 0.55 | 0.78 | 0.01 | 0.35 |
Type of adverse events (% based on total number of infusions) | |||||
Anaphylaxis | 0 | 0 | 0 | 0 | 0 |
Cardiovascular (hypertension, tachycardia) | 1 (2.9) | 2 (1.8) | 1 (3.1) | 0 | 4 (2.1) |
Gatrointestinal (nausea, vomiting) | 3 (8.8) | 2 (1.8) | 2 (6.3) | 0 | 7 (3.6) |
Muscular (stiffness, spasms) | 1 (2.9) | 1 (0.9) | 1 (3.1) | 0 | 3 (1.6) |
Neurological (headache, dizziness, somnolence) | 3 (8.8) | 11 (9.7) | 1 (3.1) | 0 | 15 (7.8) |
Opthalmologic (diplopia) | 0 | 0 | 0 | 0 | 0 |
Psychiatric (anxiety/depression, dissociation, hallucinations) | 0 | 3 (2.7) | 1 (3.1) | 0 | 4 (2.1) |
Respiratory (laryngospasms, respiratory depression, etc.) | 0 | 0 | 0 | 0 | 0 |
Skin (rash) | 0 | 1 (0.9) | 0 | 0 | 1 (0.5) |
Total number of any adverse event | 8 (23.5) | 20 (17.7) | 6 (18.8) | 0 | 34 (17.7) |
Resolved with intervention (% based on total number of any type of adverse event) | |||||
Self-resolved (resolved without intervention, and infusion not adjusted because of adverse event) | 4 (50.0) | 15 (75.0) | 3 (50.0) | – | 22 (64.7) |
Yes (stopping/reducing infusion, as-needed medications) | 4 (50.0) | 5 (25.0) | 3 (50.0) | – | 12 (35.3) |
No | 0 | 0 | 0 | – | 0 |
Several patients had multiple adverse events. “Any adverse event” is a binary measure that is positive if the patient had an adverse event during any of his or her infusions within the full duration of the IV ketamine program. Type of adverse event was calculated based on infusions.